<DOC>
	<DOCNO>NCT00680563</DOCNO>
	<brief_summary>This single arm study ass efficacy safety subcutaneous Mircera correction maintenance hemoglobin level predialysis patient renal anemia currently treat ESA . Eligible patient receive monthly subcutaneous injection initial recommend dose 1.2 micrograms/kg . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Once-Monthly Subcutaneous Mircera Treatment Chronic Renal Anemia Pre-Dialysis Patients Not Currently Treated With ESA .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; ESA therapy previous 3 month ; adequate iron status ; rapid chronic kidney disease progression . transfusion red blood cell previous 2 month ; poorly control hypertension require hospitalization previous 6 month ; significant acute chronic bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>